Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

261. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials

Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous (...) stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P CRD summary This review concluded that non-vitamin-K-antagonist oral anticoagulants seem to be associated with significant reductions in the rates of stroke or systemic embolism, haemorrhagic stroke, and major bleeding when compared with warfarin in patients with previous stroke or transient ischaemic attack. Given a number

DARE.2012

262. Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis

Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis Antiplatelet versus anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis Marrone C, Galasso G, Piccolo R, de Leva F, Paladini R, Piscione F, Santoro G CRD summary This review concluded that the rate of thromboembolic (...) and bleeding events were similar for antiplatelet and anticoagulation therapy in patients who underwent an extracardiac conduit Fontan procedure. The conclusions reflect the evidence presented, but the reliability of the evidence base is limited by the study design, sample sizes and very low numbers of events recorded across the studies. Authors' objectives To determine the incidence of thromboembolism among patients undergoing extracardiac conduit Fontan procedure who received prophylactic anticoagulation

DARE.2011

263. Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation

Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation Safety and efficacy of triple antithrombotic therapy after percutaneous coronary intervention in patients needing long-term anticoagulation Singh PP, Singh M, Bedi U, Molnar J, Arora R, Khosla S CRD summary The review (...) ST-elevation myocardial infarction or angina. Reason for anticoagulant therapy was atrial fibrillation, deep vein thrombosis, prophylaxis for left ventricle thrombus, pulmonary embolism, prosthetic valve, atrial flutter and total knee replacement. Mean age ranged from 59 years to 74 years. The mean proportion of males ranged from 37% to 75%. Follow-up ranged from six to 84 months. Definition of major and minor bleeding varied between studies. More than one author selected the studies for review

DARE.2011

264. Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism?

Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism? Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism? | Clinical Correlations Should My Patient with a Solid Tumor be Anticoagulated in the Absence of Venous Thromboembolism? September 8, 2011 By David Altszuler, Class of 2012 Faculty Peer Reviewed An empiric association between occult malignancy and thrombophlebitis has been recognized since Trousseau (...) first reported the syndrome in 1865.[1] The mechanism by which cancer predisposes to thrombophilia has not been fully elucidated; however, it is now clear that this is a symbiotic relationship.[2] The second leading cause of death in hospitalized cancer patients (and a leading .[3] There are algorithms to identify cancer patients at high risk for developing venous thromboembolism (VTE), and a recently undertaken clinical trial exploring the efficacy of anticoagulation prophylaxis in these patients

Clinical Correlations2011

265. A New Era for Anticoagulation in Atrial Fibrillation.

A New Era for Anticoagulation in Atrial Fibrillation. A new era for anticoagulation in atrial fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21870977 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Sep 15;365(11):1052-4. doi: 10.1056/NEJMe1109748. Epub 2011 Aug 27. A new era for anticoagulation in atrial fibrillation. . Comment in [N Engl J Med. 2012] Comment on [N Engl J Med. 2011] [N Engl J Med. 2009] [N Engl J Med. 2011] PMID: 21870977 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text

NEJM2011

266. New Options in Anticoagulation for Atrial Fibrillation.

New Options in Anticoagulation for Atrial Fibrillation. New options in anticoagulation for atrial fibrillation. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 21830960 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 Sep 8;365(10):952-3. doi: 10.1056/NEJMe1107516. Epub 2011 Aug 10. New options in anticoagulation for atrial fibrillation. , . Comment on [N Engl J Med. 2011] [N Engl J Med. 2009] PMID: 21830960 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Grant support Full Text Sources Medical Miscellaneous PubMed

NEJM2011

267. Low Dose Vitamin K Supplementation and Anticoagulation Control

Low Dose Vitamin K Supplementation and Anticoagulation Control Low Dose Vitamin K Supplementation and Anticoagulation Control | Clinical Correlations Low Dose Vitamin K Supplementation and Anticoagulation Control July 21, 2011 By Joanna Becker Faculty Peer Reviewed Patients who are placed on long-term warfarin ( Coumadin ) therapy are sent home with a lengthy list of restrictions to minimize variations in warfarin efficacy. The agents that can alter warfarin levels can be divided into 2 (...) categories: (1) those that interact with cytochrome P450, which metabolizes warfarin and (2) those that alter phytonadione (vitamin K) levels. The majority of inter- and intra-individual warfarin dose variability is attributable to the agents in category 1 above, which include everything from antibiotics, antihistamines, and barbiturates to alcohol and antacids. However, once one controls for these variables, oral intake of vitamin K persists as an integral factor in anticoagulation stability. Warfarin

Clinical Correlations2011

268. Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial.

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial. 21576658 2011 06 02 2011 08 02 2015 11 19 1524-4539 123 21 2011 May 31 Circulation Circulation Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant (...) therapy (RE-LY) trial. 2363-72 10.1161/CIRCULATIONAHA.110.004747 Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median

EvidenceUpdates2011

269. Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes

Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes Bloomfield HE, Krause A, Greer N, Taylor BC, MacDonald R, Rutks I, Reddy P, Wilt TJ CRD summary The review concluded that patient (...) self-testing/self-management was associated with significantly fewer deaths and thromboembolic events, without increasing bleeding complications, for patients requiring long-term anticoagulation with vitamin K antagonists compared with usual clinic care; however, the evidence was of moderate or low strength. The review had several limitations, suggesting its conclusions should be interpreted with caution. Authors' objectives To determine whether patient self-testing, alone or in combination

DARE.2011

270. Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran.

Anticoagulant Options - Why the FDA Approved a Higher but Not a Lower Dose of Dabigatran. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File (...) 1 selected item: 21488759 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2011 May 12;364(19):1788-90. doi: 10.1056/NEJMp1103050. Epub 2011 Apr 13. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran. 1 , , . 1 Division of Cardiovascular and Renal Products, Office of New Drugs, Center

NEJM2011

271. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort

Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort 20966417 2010 11 30 2010 12 22 2016 11 22 1524-4628 41 12 2010 Dec Stroke Stroke Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. 2731-8 10.1161/STROKEAHA.110.590257 The risk (...) of stroke in patients with atrial fibrillation (AF) is not homogeneous, and various clinical risk factors have informed the development of stroke risk stratification schemes (RSS). Among anticoagulated cohorts, the emphasis should be on the identification of patients who remain at high risk for stroke despite anticoagulation. We investigated predictors of thromboembolism (TE) risk in an anticoagulated AF clinical trial cohort (n = 7329 subjects) and tested the predictive value of contemporary RSS

EvidenceUpdates2011

272. Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs

Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation The HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs 21111555 2011 01 07 2011 04 05 2013 11 21 1558-3597 57 2 2011 Jan 11 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients (...) with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. 173-80 10.1016/j.jacc.2010.09.024 The purpose of this study was to investigate predictors of bleeding in a cohort of anticoagulated patients and to evaluate the predictive value of several bleeding risk stratification schemas. The risk of bleeding during antithrombotic therapy in patients with atrial fibrillation (AF) is

EvidenceUpdates2011

274. A Synthesis of the Evidence: Safe and Effective Anticoagulation in the Outpatient Setting

A Synthesis of the Evidence: Safe and Effective Anticoagulation in the Outpatient Setting Management Briefs Search the HSR&D website Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs Health Services Research & Development Management Briefs Management Briefs: Provide VA senior managers with results from VA Health Services Research in a concise and timely manner. , February 2017, Issue 122 , February 2017

Veterans Affairs - R&D2011

275. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement

Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement 20971245 2010 10 25 2010 11 10 2010 10 25 1552-6259 90 5 2010 Nov The Annals of thoracic surgery Ann. Thorac. Surg. Efficacy and safety of very low-dose self-management of oral anticoagulation in patients with mechanical heart valve replacement. 1487-93 10.1016/j.athoracsur.2010.06.069 Self-management improves oral anticoagulation control. Here we provide data (...) of a preplanned interim analysis of very low-dose early self-controlled anticoagulation. In a prospective, randomized, multicenter trial, 1,137 patients performed low-dose international normalized ratio (INR) self-management with a target INR range of 1.8. to 2.8 for aortic valve replacement recipients and 2.5 to 3.5 for mitral or double valve replacement recipients for the first six postoperative months. Thereafter, 379 patients continued to achieve the aforementioned INR target range (LOW group), whereas

EvidenceUpdates2011

276. The dental patient on oral anticoagulant medication: a literature review

The dental patient on oral anticoagulant medication: a literature review The dental patient on oral anticoagulant medication: a literature review The dental patient on oral anticoagulant medication: a literature review Kosyfaki P, Att W, Strub JR CRD summary This review concluded that different anticoagulation strategies were associated with varying complications, during dental treatment. There was insufficient evidence to determine the safest successful dental treatment. The authors (...) ’ conclusions were suitably cautious and appropriate, reflecting the limited evidence available. Authors' objectives To evaluate the relationship between anticoagulant medication and dental treatment. Searching PubMed was searched for relevant English-language publications from 1988 to October 2010. Search terms were reported. High-yield journals (not specified) and relevant bibliographies were manually screened. Study selection Eligible for inclusion were studies assessing the relationship between oral

DARE.2011

277. [Biology of haemostasis disorders: lupus anticoagulant detection]

[Biology of haemostasis disorders: lupus anticoagulant detection] Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique [Biology of haemostasis disorders: lupus anticoagulant detection] Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique [Biology of haemostasis disorders: lupus anticoagulant detection] Haute Autorité de Santé Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Haute Autorité de Santé. Biologie des anomalies de l'hémostase : détection d'un anticoagulant de type lupique. [Biology of haemostasis disorders: lupus anticoagulant detection] . Paris: Haute Autorité de Santé (HAS). 2011 Authors' objectives The National Salaried Workers' Health Insurance Fund (CNAMTS) asked HAS to assess the value of the different laboratory tests for haemostasis abnormalities

Health Technology Assessment (HTA) Database.2011

278. Oral anticoagulation with warfarin - 4th edition

Oral anticoagulation with warfarin - 4th edition Guidelines on oral anticoagulation with warfarin – fourth edition - Keeling - 2011 - British Journal of Haematology - Wiley Online Library By continuing to browse this site you agree to us using cookies as described in Navigate this article Previous article in issue: Secondary cancers following allogeneic haematopoietic cell transplantation in adults Next article in issue: Lenalidomide downregulates the cell survival factor, interferon regulatory (...) for and management of patients on warfarin. This guideline replaces the previous BCSH guidelines on oral anticoagulants ( ; ). 1. Indications for warfarin and recommended target international normalized ratio (INR) This guideline refers to target INRs rather than target ranges, although the target range is generally taken to be within 0·5 of the target, i.e. a target INR 2·5 equates to a target range of 2·0–3·0. Specifying tighter target ranges for fully anticoagulated patients e.g. 2·0–2·5 or 3·5–4·0 does

British Committee for Standards in Haematology2011

279. Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer.

Interventions other than anticoagulants and systemic antibiotics for prevention of central venous catheter-related infections in children with cancer. BACKGROUND: Use of central venous catheters (CVC) in treatment of children with cancer is associated with infective complications. Current evidence-based guidelines to prevent catheter-related infections are mainly relevant to the adult population. They are not cancer (especially not childhood cancer) specific. Two existing Cochrane reviews have (...) looked at prophylactic antibiotics and anticoagulants to prevent CVC-related infections. OBJECTIVES: The primary objective was to find which interventions, if any, were effective in preventing CVC-related infections in children with cancer. Further objectives were to examine the effectiveness of each intervention in the following subgroups: implanted versus external catheters, haematological versus non-haematological malignancies, and in those receiving haematopoietic stem cell transplants (HSCT

Cochrane2010